This is a two part study. Part A is a multiple-ascending dose study in up to 6 different
groups of healthy subjects, with approximately 12 subjects in each of the groups. Part A will
allow investigation of up to 6 different doses of LY2979165. The drug will be administered
for a total of 14 days. Subjects will be resident in the clinical research unit (CRU) from
Day -1 (the day before dosing) until Day 15.
Part B will investigate a dose of LY2979165 previously administered in Part A in up to 12
subjects. The drug will be administered for a total of 14 days. In addition to the same
assessments as would have been completed in Part A, subjects in Part B will also have
cerebrospinal fluid samples taken from the lower lumbar region of their spine.